List of Excipients in Branded Drug DULOXETINE D/R

Generic Drugs Containing DULOXETINE D/R

Company	Ingredient	NDC	Excipient
Direct_Rx	duloxetine d/r	72189-608	AMMONIA
Direct_Rx	duloxetine d/r	72189-608	CROSCARMELLOSE SODIUM
Direct_Rx	duloxetine d/r	72189-608	FERROSOFERRIC OXIDE
Direct_Rx	duloxetine d/r	72189-608	GELATIN
Direct_Rx	duloxetine d/r	72189-608	HYPROMELLOSE PHTHALATE
Direct_Rx	duloxetine d/r	72189-608	HYPROMELLOSES
Direct_Rx	duloxetine d/r	72189-608	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in DULOXETINE D/R?

# Of NDCs	Excipient
1	ALCOHOL
4	AMMONIA
1	BUTYL ALCOHOL
3	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 2
1	FERRIC OXIDE YELLOW
4	FERROSOFERRIC OXIDE

Excipient Strategy and Commercial Opportunities for DULOXETINE D/R

Last updated: March 4, 2026

What are the key formulation considerations for DuloXetine D/R?

Duloxetine delayed-release (D/R) formulations primarily target chronic conditions such as depression, anxiety, and neuropathy. The choice of excipients is critical to ensure stability, bioavailability, and patient compliance.

• Core Components:

  • Polymer matrix: Typically enteric coatings such as methacrylic acid copolymers prevent premature release in the stomach.
  • Plasticizers: Used in coatings for flexibility—common examples include triethyl citrate and dibutyl phthalate.
  • Fillers: Microcrystalline cellulose, lactose, and mannitol aid in compressibility and dosing uniformity.
  • Disintegrants: Croscarmellose sodium or sodium starch glycolate facilitate tablet breakup.

• Formulation Challenges:

  • Ensuring controlled release over 12-24 hours.
  • Minimizing dose variability due to excipient interactions.
  • Achieving stability in various storage conditions.

Note: Use of minimal excipients compatible with long-term stability and manufacturing ease is a priority.

How does excipient selection impact commercial opportunities?

Efficient excipient strategies affect manufacturing costs, product efficacy, and patient adherence—factors critical to market success.

• Cost Management:

  • Use of standard excipients like microcrystalline cellulose reduces production costs.
  • Flexible formulations with readily available excipients improve supply chain resilience.

• Product Differentiation:

  • Incorporating advanced biodegradable or mucoadhesive polymers might enable extended release profiles or improved GI tolerability.
  • Electronically active excipients could facilitate dose personalization.

• Regulatory Considerations:

  • Use of well-characterized excipients expedites approval.
  • Patentability of novel excipients or combinations can create market exclusivity.

Opportunities:

Opportunity	Description	Market Impact
Extended-release formulations	Leverage proprietary excipients for longer half-life	Higher dosing convenience, improved adherence
Reduced excipient load	Minimize excipients to reduce potential side-effects	Enhanced safety profile
Biodegradable excipients	Use eco-friendly materials	Market appeal for sustainability

What is the competitive landscape for excipient innovation in DuloXetine D/R?

Other companies have explored novel excipients and formulations targeting enhanced bioavailability and patient compliance:

• SinuSys developed a mucoadhesive formulation utilizing chitosan derivatives.
• Alchemie created biodegradable polymer coatings with controlled erosion properties.
• Capsugel offers custom excipient blends promoting consistent dissolution.

Commercial success depends on regulatory approval, manufacturing efficiency, and patient preference.

What are the regulatory implications for excipient strategies?

Excipients designated as inactive ingredients are subject to regulatory review as part of the drug approval process.

• FDA Guidance:

  • Emphasizes excipient safety, stability, and functionality.
  • Requires detailed excipient characterization and compatibility studies.

• EMA Guidelines:

  • Focus on excipient batch uniformity and excipient-drug interactions.

Adopting novel excipients requires comprehensive documentation, potentially extending development timelines but opening patent avenues.

What are the key takeaways for manufacturing and R&D?

• Select excipients based on stability, bioavailability, and manufacturing compatibility.
• Use existing regulatory accepted excipients to streamline approval.
• Invest in proprietary excipients for differentiation and patent protection.
• Explore biodegradable and mucoadhesive polymers to meet market demands.
• Consider cost implications alongside innovation to maximize commercial viability.

FAQs

1. What are the primary excipients used in duloxetine D/R formulations?
   Microcrystalline cellulose, provide disintegrants; methacrylic acid copolymers, for enteric coating; plasticizers like triethyl citrate; and fillers such as lactose.

2. How can excipient selection influence patient compliance?
   By enabling once-daily dosing, minimizing side-effects, and providing stable, easy-to-swallow tablets.

3. Are there opportunities for novel excipients in duloxetine formulations?
   Yes, biodegradable polymers, mucoadhesive agents, and sustained-release matrix materials can offer differentiation.

4. What regulatory challenges exist with new excipients?
   Regulatory agencies require extensive safety and compatibility data; patent protection may be limited for some excipients.

5. How do excipient costs impact market competitiveness?
   Lower-cost, readily available excipients reduce production costs, offering pricing advantages over competitors.

Key Takeaways

• Excipients influence drug stability, bioavailability, and patient adherence for duloxetine D/R products.
• Selecting appropriate excipients impacts regulatory approval, manufacturing efficiency, and market differentiation.
• Innovations such as biodegradable or mucoadhesive excipients provide competitive advantages.
• Regulatory pathways favor well-characterized excipients but open opportunities through novel, patentable excipients.
• Cost-effective and performance-enhancing excipient strategies support commercial success.

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Engineering Studies for Extended-Release Solid Oral Dosage Forms.
[2] European Medicines Agency. (2021). Guideline on pharmaceutical development of medicines for human use.
[3] Marucci, M., et al. (2020). Excipient interactions and stability considerations in the formulation of oral controlled-release pharmaceuticals. International Journal of Pharmaceutics, 577, 119057.
[4] Smith, J. T., & Lee, D. S. (2019). Advances in excipient technology for improving drug delivery. Advanced Drug Delivery Reviews, 144, 1-15.